Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.

Abstract:

:Several authors question the potential benefit of preoperative magnetic resonance imaging (MRI) against the background of possible overdiagnosis, false-positive findings, and unnecessary resections in patients with newly diagnosed breast cancer. In order to reveal a better selection of patients who should undergo preoperative MRI after histological confirmed breast cancer, the present analysis was implemented. We aimed to evaluate the influence of preoperative breast MRI in patients with newly diagnosed breast cancer to find subgroups of patients that are most likely to benefit from preoperative MRI by the detection of occult malignant foci. A total of 1102 consecutive patients who underwent treatment for primary breast cancer between 2002 and 2013 were retrospectively analyzed. All patients underwent triple assessment by breast ultrasound, mammography, and bilateral breast MRI. MRI findings not seen on conventional imaging that suggested additional malignant disease was found in 344 cases (31.2 %). Histological confirmed malignant foci were found in 223 patients (20.2 %) within the index breast and in 28 patients (2.5 %) in the contralateral breast. The rate of false-negative biopsies was 31 (2.8 %) and 62 (5.6 %), respectively. Premenopausal women (p = 0.024), lobular invasive breast cancer (p = 0.02) as well as patients with high breast density [American College of Radiology (ACR) 3 + 4; p = 0.01] were significantly associated with additional malignant foci in the index breast. Multivariate analysis confirmed lobular histology (p = 0.041) as well as the co-factors "premenopausal stage" and "high breast density (ACR 3+4)" (p = 0.044) to be independently significant. Previous studies revealed that breast MRI is a reliable tool for predicting tumor extension as well as for the detection of additional ipsilateral and contralateral tumor foci in histological confirmed breast cancer. In the present study, we demonstrate that especially premenopausal patients with high breast density as well as patients with lobular histology seem to profit from preoperative MRI.

authors

Debald M,Abramian A,Nemes L,Döbler M,Kaiser C,Keyver-Paik MD,Leutner C,Höller T,Braun M,Kuhl C,Kuhn W,Schild HH

doi

10.1007/s10549-015-3556-3

subject

Has Abstract

pub_date

2015-10-01 00:00:00

pages

531-7

issue

3

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-015-3556-3

journal_volume

153

pub_type

杂志文章
  • Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo.

    abstract::The glycolytic phenotype is a widespread phenomenon in solid cancer forms, including breast cancer. Dichloroacetate (DCA) has recently been proposed as a novel and relatively non-toxic anti-cancer agent that can reverse the glycolytic phenotype in cancer cells through the inhibition of pyruvate dehydrogenase kinase. W...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0435-9

    authors: Sun RC,Fadia M,Dahlstrom JE,Parish CR,Board PG,Blackburn AC

    更新日期:2010-02-01 00:00:00

  • Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea.

    abstract::Recent compelling evidence indicates that mutation, aberrant expression, and dysregulation of microRNA (miRNA) biogenesis are implicated in cancer development and progression. Based on the important role of miRNA biogenesis pathway in carcinogenesis, we hypothesized that genetic variations in this pathway genes may pl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1656-2

    authors: Sung H,Lee KM,Choi JY,Han S,Lee JY,Li L,Park SK,Yoo KY,Noh DY,Ahn SH,Kang D

    更新日期:2011-12-01 00:00:00

  • Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.

    abstract::Estrogenic steroids, such as estradiol, are known to play a crucial role in the development and growth of hormone-dependent breast cancer. Steroid sulfatase (STS) inhibitors that can prevent the biosynthesis of these steroids via the sulfatase pathway offer therapeutic potential. We show here the in vivo profile, incl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9769-3

    authors: Foster PA,Chander SK,Parsons MF,Newman SP,Woo LW,Potter BV,Reed MJ,Purohit A

    更新日期:2008-09-01 00:00:00

  • Quantitative analysis of mitochondrial DNA 4977-bp deletion in sporadic breast cancer and benign breast diseases.

    abstract::The mitochondrial DNA (mtDNA) 4977-bp deletion (DeltamtDNA(4977) mutation) is one of the most frequently observed mtDNA mutations in human tissues and may play a role in carcinogenesis. Only a few studies have evaluated DeltamtDNA(4977) mutation in breast cancer tissue, and the findings have been inconsistent, which m...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9613-9

    authors: Ye C,Shu XO,Wen W,Pierce L,Courtney R,Gao YT,Zheng W,Cai Q

    更新日期:2008-04-01 00:00:00

  • Factors predicting in-breast tumor recurrence after breast-conserving surgery.

    abstract:PURPOSE:The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival. METHODS:A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0187-y

    authors: Mechera R,Viehl CT,Oertli D

    更新日期:2009-07-01 00:00:00

  • Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.

    abstract::The aromatase inhibitor 10-propargylestr-4-ene-3,17-dione (PED) has been evaluated in vivo as an anticancer agent. Prolonged administration of PED to rats bearing dimethylbenzanthracene-induced mammary tumors resulted in significant regression of hormone-responsive tumors within several days. Greater than 50% regressi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00682696

    authors: Zimniski SJ,Brandt ME,Covey DF,Puett D

    更新日期:1993-01-01 00:00:00

  • Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.

    abstract:PURPOSE:Insertion of radiopaque markers is helpful for tumor localization in patients receiving neoadjuvant chemotherapy (NAC) followed by breast-conserving surgery (BCS). The aim of this retrospective study was to investigate the pathologic margin status in patients with single or double marker insertion. METHODS:We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05907-9

    authors: Cha C,Lee J,Kim D,Park S,Bae SJ,Eun NL,Ahn SG,Son EJ,Jeong J

    更新日期:2020-12-01 00:00:00

  • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

    abstract::Tamoxifen is metabolized into endoxifen, a potent antagonist of the estrogen receptor, in part through cytochrome p450 (CYP) 2D6. Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-013-2700-1

    authors: Ruddy KJ,Desantis SD,Gelman RS,Wu AH,Punglia RS,Mayer EL,Tolaney SM,Winer EP,Partridge AH,Burstein HJ

    更新日期:2013-10-01 00:00:00

  • Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

    abstract::Medroxyprogesterone acetate (MPA) is well recognized to have beneficial effects for the treatment of advanced breast cancer which are comparable to those achieved with other forms of endocrine therapy. Using mammary tumors induced in the rat by dimethylbenz(a)anthracene (DMBA) as a model, we have studied the possibili...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665803

    authors: Labrie F,Li S,Bélanger A,Côté J,Mérand Y,Lepage M

    更新日期:1993-01-01 00:00:00

  • Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.

    abstract:PURPOSE:Although breast cancer in young women accounts for <10% of diagnoses annually, tumors in young patients exhibit more aggressive characteristics and higher mortality rates. Determination of the frequency of germline mutations in cancer predisposition genes is needed to improve the understanding of breast cancer ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4291-8

    authors: Rummel SK,Lovejoy L,Shriver CD,Ellsworth RE

    更新日期:2017-08-01 00:00:00

  • Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy.

    abstract::Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory sh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666155

    authors: Chen WT,Lee CC,Goldstein L,Bernier S,Liu CH,Lin CY,Yeh Y,Monsky WL,Kelly T,Dai M

    更新日期:1994-01-01 00:00:00

  • Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US.

    abstract::Recent breast cancer treatment studies conducted in large urban settings have reported racial disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused evaluation of black-white differences in receipt and completion of chemotherapy for breast cancer in a primarily rural regio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1916-1

    authors: Lipscomb J,Gillespie TW,Goodman M,Richardson LC,Pollack LA,Ryerson AB,Ward KC

    更新日期:2012-05-01 00:00:00

  • Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ.

    abstract::Although preoperative magnetic resonance imaging (MRI) can detect mammographically occult contralateral breast cancers (CBCs) among women with ductal carcinoma in situ (DCIS), the impact of MRI on the incidence of subsequent CBC events is unclear. We examined whether MRI use decreases CBC occurrences and detection of ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3858-0

    authors: Wang SY,Long JB,Killelea BK,Evans SB,Roberts KB,Silber A,Gross CP

    更新日期:2016-07-01 00:00:00

  • The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.

    abstract:BACKGROUND:Telomerase is a ribonucleoprotein enzyme that synthesises telomeres in human germ cells, embryogenesis and in cancer, maintaining chromosomal length, stability and cellular immortality. The hTERT gene is the rate-limiting determinant of telomerase reactivation during immortalization and malignant transformat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9622-8

    authors: Salhab M,Jiang WG,Newbold RF,Mokbel K

    更新日期:2008-05-01 00:00:00

  • Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium.

    abstract::We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen receptor (ER) subtypes. Tagging single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina Exo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3672-0

    authors: Ruiz-Narváez EA,Haddad SA,Lunetta KL,Yao S,Bensen JT,Sucheston-Campbell LE,Hong CC,Haiman CA,Olshan AF,Ambrosone CB,Palmer JR

    更新日期:2016-01-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract::The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1429-y

    authors: Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期:2011-06-01 00:00:00

  • Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.

    abstract:PURPOSE:To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS:A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-u...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4491-2

    authors: Siegelmann-Danieli N,Katzir I,Landes JV,Segal Y,Bachar R,Rabinovich HR,Bialik M,Azuri J,Porath A,Lomnicky Y

    更新日期:2018-01-01 00:00:00

  • Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

    abstract::Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry (ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this study was to disclose the prognostic significance of different morphological categories of ICC-positive cells according to treatment status an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2439-8

    authors: Synnestvedt M,Borgen E,Schlichting E,Schirmer CB,Renolen A,Giercksky KE,Nesland JM,Naume B

    更新日期:2013-04-01 00:00:00

  • BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

    abstract::The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in BRCA1 and BRCA2. We have tested...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0153-8

    authors: Neuhausen SL,Ozcelik H,Southey MC,John EM,Godwin AK,Chung W,Iriondo-Perez J,Miron A,Santella RM,Whittemore A,Andrulis IL,Buys SS,Daly MB,Hopper JL,Seminara D,Senie RT,Terry MB,Breast Cancer Family Registry.

    更新日期:2009-07-01 00:00:00

  • Preoperative paravertebral blocks for the management of acute pain following mastectomy: a cost-effectiveness analysis.

    abstract:PURPOSE:Preoperative paravertebral blocks (PPVBs) are routinely used for treating post-mastectomy pain, yet uncertainties remain about the cost-effectiveness of this modality. We aim to evaluate the cost-effectiveness of PPVBs at common willingness-to-pay (WTP) thresholds. METHODS:A decision analytic model compared tw...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-017-4371-9

    authors: Offodile AC 2nd,Sheckter CC,Tucker A,Watzker A,Ottino K,Zammert M,Padula WV

    更新日期:2017-10-01 00:00:00

  • Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure.

    abstract:BACKGROUND:The Z0011 trial initiated a paradigm shift in the axillary treatment of breast cancer patients with a positive sentinel lymph node biopsy (SLNB), disregarding patients with a positive ultrasound-guided lymph node biopsy (UGLNB). We examined whether relevant differences exist between these patients to determi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4342-1

    authors: Verheuvel NC,Voogd AC,Tjan-Heijnen VCG,Siesling S,Roumen RMH

    更新日期:2017-10-01 00:00:00

  • Droloxifene, a new antiestrogen: its role in metastatic breast cancer.

    abstract::Droloxifene, a new antiestrogen, has theoretical advantages over tamoxifen based on preclinical data. These include higher affinity to the estrogen receptor, higher antiestrogenic to estrogenic ratio, and more effective inhibition of cell growth and division in ER positive cell lines, as well as less toxicity, includi...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF00689679

    authors: Rauschning W,Pritchard KI

    更新日期:1994-01-01 00:00:00

  • Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.

    abstract::Estrogen receptor beta (ERbeta) is widely expressed in mammary epithelium. ERbeta expression is reported to decline during carcinogenesis of the breast and other tissues. In this study, we examined the consequences of a loss of ERbeta expression in mammary epithelial cells. We knocked down ERbeta transcript levels in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0413-2

    authors: Treeck O,Lattrich C,Springwald A,Ortmann O

    更新日期:2010-04-01 00:00:00

  • Action of "pure" antiestrogens in inhibiting estrogen receptor action.

    abstract::The mechanism of action of the pure antiestrogens ICI 164384 and ICI 182780 has been investigated. Both antagonists are steroidal antiestrogens with 7 alpha-alkylamide side-chains. The antiestrogens reduce the cellular content of the estrogen receptor by reducing the half-life of the protein. A potential mechanism for...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00689686

    authors: Parker MG

    更新日期:1993-01-01 00:00:00

  • Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

    abstract:AIMS:Rapamycin and its analogues are currently being tested in clinical trials as novel-targeted anticancer agents. Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. The aims of this study were to ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9746-x

    authors: Noh WC,Kim YH,Kim MS,Koh JS,Kim HA,Moon NM,Paik NS

    更新日期:2008-08-01 00:00:00

  • Assessing the additional surgical risk of contralateral prophylactic mastectomy and immediate breast implant reconstruction.

    abstract:INTRODUCTION:There has been a sharp rise in the rate of contralateral prophylactic mastectomy over the last decade, despite the low incidence of new primary cancers predicted for the contralateral breast. This study compares the postoperative complication rates between the diseased breast treated with mastectomy and th...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05460-0

    authors: Nealon KP,Sobti N,Gadd M,Specht M,Liao EC

    更新日期:2020-01-01 00:00:00

  • Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer.

    abstract::Histological grading of 160 primary infiltrating breast carcinomas showed that both oestrogen and progesterone receptor status are strongly related to grade, tumours that are receptor positive tending to be of lower grade than the receptor negative. The nuclear factors used in grading were those that determined this a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806938

    authors: Thoresen S,Thorsen T,Tangen M,Hartveit F

    更新日期:1982-01-01 00:00:00

  • Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk.

    abstract::Integrins are cell surface receptors, which mediate cell-to-cell and cell-to-extracellular matrix adhesion. Some of them, e.g. alpha(V)beta(3), alpha(IIb)beta(3) and alpha(2)beta(1), have been suggested as key players for cancer development and tumor metastasis. Two polymorphisms in the gene for the alpha(2) component...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-9089-4

    authors: Langsenlehner U,Renner W,Yazdani-Biuki B,Eder T,Wascher TC,Paulweber B,Clar H,Hofmann G,Samonigg H,Krippl P

    更新日期:2006-05-01 00:00:00

  • Transforming growth factor-beta in breast cancer: a working hypothesis.

    abstract::Transforming Growth Factor-beta (TGF beta) is the most potent known inhibitor of the progression of normal mammary epithelial cells through the cell cycle. During the early stages of breast cancer development, the transformed epithelial cells appear to still be sensitive to TGF beta-mediated growth arrest, and TGF bet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1005865812918

    authors: Reiss M,Barcellos-Hoff MH

    更新日期:1997-08-01 00:00:00

  • Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.

    abstract:PURPOSE:Younger women diagnosed with breast cancer have poorer prognoses and higher mortality compared to older women. Young black women have higher incidence rates of breast cancer and more aggressive subtypes than women of other races/ethnicities. In this study, we examined recent trends and variations in breast canc...

    journal_title:Breast cancer research and treatment

    pub_type: 历史文章,杂志文章

    doi:10.1007/s10549-018-4699-9

    authors: Shoemaker ML,White MC,Wu M,Weir HK,Romieu I

    更新日期:2018-06-01 00:00:00